Compare AngloGold Ashanti Limited (AU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs State Street SPDR S&P Biotech ETF — how do they compare? AngloGold Ashanti Limited trades at $97.6 (market cap $49.28B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: AngloGold Ashanti Limited pays a 4.64% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, AngloGold Ashanti Limited nearer its low. Which is the better fit depends on your goals.
| AU | XBI | |
|---|---|---|
Market Cap | $49.28B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $128.26 | $164.28 |
52-Week Low | $52.15 | $86.92 |
Enterprise Value | $48.29B | — |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $97.89, up 0.66% with strong bullish momentum from moving averages. The stock shows robust fundamentals with 32.19% net income margin and 46.5% ROE, supported by rising gold prices and production growth. Recent Q2 2026 earnings beat expectations with $727 million free cash flow, while the company maintains a $2 billion buyback program. Technical indicators show overbought conditions with RSI at 79.27, but institutional interest remains strong with multiple recent position increases.
Outlook remains positive with analyst consensus target of $120.33 (23% upside) and 64% buy ratings. Key catalysts include H2 production growth and shareholder returns, though risks include gold price volatility and operational challenges. The stock trades at reasonable valuations (P/E 13.06, EV/EBITDA 7.58) with improving balance sheet strength (debt-to-asset ratio declining to 15.59%).
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
